For more information, please visit COPD is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. Our cross-functional team operates at the intersection of biology and software technology. Desirable office location is offered Company
Are you a Current or Former Employee? kununu employer branding profile Between 2007-2013, Pearl’s four investors backed it with $167.5 million, allowing the progression of key therapeutic areas.Subsequently, in 2013, AstraZeneca acquired Pearl to expand and strengthen its Notably, Pearl’s lead combination medicine was recently launched in the US during the first quarter of 2017 and has regulatory submission acceptance in EU for COPD. The Company develops therapeutics for the treatment of respiratory diseases.
Pearl Therapeutics, a subsidiary of AstraZeneca, develops combination therapies and formulations of inhaled drugs for chronic respiratory diseases such as asthma and COPD.
This technology platform will allow AstraZeneca to explore combinations of existing and novel technologies, including a triple fixed dose combination (LABA/LAMA and inhaled corticosteroid) which could be accelerated into Phase II clinical development.Under the terms of the agreement, AstraZeneca will acquire 100% of Pearl’s shares for initial consideration of $560 million payable on completion.
We encourage you to read the privacy policy of every website you visit.Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.Head of Respiratory Global Medicines Development and CEO of Pearl TherapeuticsPhase III/Reg.
ID: SkVqV1l8fA==
Desirable office location in 1 of 1 reviews LABA/LAMA combinations are expected to become an important new class of treatment for COPD.
Paid Parental Leave is offered Morristown Ability to work remotely in 1 of 1 reviews
We encourage you to read the privacy policy of every website you visit.Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio Parking in 1 of 1 reviews
It affects an estimated 210 million people worldwide and is predicted to be the third leading cause of death by 2020. Flexible spending account in 1 of 1 reviews Excellent On site cafeteria is offered Subpar I would like to thank Pearl’s partners, management team and everyone on the Pearl team for the extraordinary contributions that they have made to progress the company to this stage.
Employee events is offered
Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.